KR102579848B1 - 항진균 화합물 - Google Patents

항진균 화합물 Download PDF

Info

Publication number
KR102579848B1
KR102579848B1 KR1020177013730A KR20177013730A KR102579848B1 KR 102579848 B1 KR102579848 B1 KR 102579848B1 KR 1020177013730 A KR1020177013730 A KR 1020177013730A KR 20177013730 A KR20177013730 A KR 20177013730A KR 102579848 B1 KR102579848 B1 KR 102579848B1
Authority
KR
South Korea
Prior art keywords
compound
formula
salt
aspergillus
genus
Prior art date
Application number
KR1020177013730A
Other languages
English (en)
Korean (ko)
Other versions
KR20170088850A (ko
Inventor
미히로 스노세
토마스 크리스토퍼 콜리
카즈히로 이토
가세 라페로트
피터 스트롱
Original Assignee
풀모사이드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 풀모사이드 리미티드 filed Critical 풀모사이드 리미티드
Publication of KR20170088850A publication Critical patent/KR20170088850A/ko
Application granted granted Critical
Publication of KR102579848B1 publication Critical patent/KR102579848B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
    • G06F1/26—Power supply means, e.g. regulation thereof
    • G06F1/32—Means for saving power
    • G06F1/3203—Power management, i.e. event-based initiation of a power-saving mode
    • G06F1/3234—Power saving characterised by the action undertaken
    • G06F1/325—Power saving in peripheral device
    • G06F1/3268—Power saving in hard disk drive
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C11/00—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor
    • G11C11/21—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements
    • G11C11/34—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices
    • G11C11/40—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors
    • G11C11/401—Digital stores characterised by the use of particular electric or magnetic storage elements; Storage elements therefor using electric elements using semiconductor devices using transistors forming cells needing refreshing or charge regeneration, i.e. dynamic cells
    • G11C11/4063—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing
    • G11C11/407—Auxiliary circuits, e.g. for addressing, decoding, driving, writing, sensing or timing for memory cells of the field-effect type
    • G11C11/4074—Power supply or voltage generation circuits, e.g. bias voltage generators, substrate voltage generators, back-up power, power control circuits

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177013730A 2014-12-05 2015-12-04 항진균 화합물 KR102579848B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196662.2 2014-12-05
EP14196662 2014-12-05
PCT/GB2015/053731 WO2016087878A1 (en) 2014-12-05 2015-12-04 Antimycotic compound

Publications (2)

Publication Number Publication Date
KR20170088850A KR20170088850A (ko) 2017-08-02
KR102579848B1 true KR102579848B1 (ko) 2023-09-18

Family

ID=52006914

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177013730A KR102579848B1 (ko) 2014-12-05 2015-12-04 항진균 화합물

Country Status (19)

Country Link
US (12) US10106531B2 (zh)
EP (2) EP3227277B1 (zh)
JP (2) JP6666345B2 (zh)
KR (1) KR102579848B1 (zh)
CN (2) CN107001343B (zh)
AU (1) AU2015356795B2 (zh)
BR (1) BR112017008481B1 (zh)
CA (1) CA2963625C (zh)
DK (2) DK3227278T3 (zh)
EA (1) EA033736B1 (zh)
ES (2) ES2786374T3 (zh)
HK (1) HK1244795A1 (zh)
HU (2) HUE048905T2 (zh)
IL (1) IL251631B (zh)
MX (1) MX370412B (zh)
PL (1) PL3227277T3 (zh)
PT (1) PT3227277T (zh)
SG (1) SG11201702835RA (zh)
WO (2) WO2016087880A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001343B (zh) 2014-12-05 2020-12-11 普尔莫赛德有限公司 抗真菌的化合物
WO2016097761A1 (en) 2014-12-18 2016-06-23 Pulmocide Limited 4,5-dihydro-6h-thieno[3,2-d]benzazepine derivatives and their use to treat respiratory syncytial virus (rsv) infections
SG11201708007VA (en) 2015-05-21 2017-12-28 Pulmocide Ltd Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.
WO2017093491A1 (en) * 2015-12-04 2017-06-08 Pulmocide Limited Antimycotic triazole compound
WO2018096405A1 (en) * 2016-11-28 2018-05-31 Cellix Bio Private Limited Compositions and methods for the treatment of oral infectious diseases
WO2018115319A2 (en) 2016-12-23 2018-06-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
GB201917867D0 (en) 2019-12-06 2020-01-22 Pulmocide Ltd Polymorphs
EP3858357A1 (en) * 2020-01-28 2021-08-04 Diaccurate Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib
RU2770598C1 (ru) * 2021-06-29 2022-04-18 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) ПРИМЕНЕНИЕ ПРОТИВОГРИБКОВОГО СРЕДСТВА НА ОСНОВЕ 2-((4-R1-5-R2-3-(ЭТОКСИКАРБОНИЛ)ТИОФЕН-2-ИЛ)АМИНО)-4-ОКСО-4-R3-БУТ-2-ЕНОВЫХ КИСЛОТ ПО ОТНОШЕНИЮ К Candida aldicans

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
EP0318214B1 (en) 1987-11-20 1994-12-14 Schering Corporation Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5403937A (en) * 1993-04-30 1995-04-04 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
CO4520281A1 (es) 1993-12-21 1997-10-15 Schering Corp Antifungicos de tetrahidrofurano
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2199291T3 (es) 1995-06-02 2004-02-16 Schering Corporation Antifungicos de tetrahidrofurano.
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
MXPA03009021A (es) 2001-04-03 2004-02-12 Schering Corp Composicion antifungal con biodisponibilidad aumentada.
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2013012848A1 (en) * 2011-07-18 2013-01-24 Merck Patent Gmbh Benzamides
US9346791B2 (en) 2011-09-07 2016-05-24 The Johns Hopkins University Itraconazole analogs and use thereof
CN107001343B (zh) 2014-12-05 2020-12-11 普尔莫赛德有限公司 抗真菌的化合物

Also Published As

Publication number Publication date
JP2017536382A (ja) 2017-12-07
JP6669751B2 (ja) 2020-03-18
US20210048874A1 (en) 2021-02-18
IL251631A0 (en) 2017-06-29
BR112017008481B1 (pt) 2022-09-06
US20230295133A1 (en) 2023-09-21
US20170320858A1 (en) 2017-11-09
EP3227277A1 (en) 2017-10-11
PT3227277T (pt) 2020-04-14
US10106531B2 (en) 2018-10-23
US10662179B2 (en) 2020-05-26
EP3227278B1 (en) 2020-02-05
US10858345B2 (en) 2020-12-08
EP3227277B1 (en) 2020-02-05
ES2790875T3 (es) 2020-10-29
HK1244795A1 (zh) 2018-08-17
JP2017536385A (ja) 2017-12-07
JP6666345B2 (ja) 2020-03-13
NZ730861A (en) 2021-04-30
EA033736B1 (ru) 2019-11-20
US11661415B2 (en) 2023-05-30
EP3227278A1 (en) 2017-10-11
US10800762B2 (en) 2020-10-13
AU2015356795B2 (en) 2020-01-16
US10344022B2 (en) 2019-07-09
CA2963625A1 (en) 2016-06-09
DK3227278T3 (da) 2020-04-27
CA2963625C (en) 2023-08-22
PL3227277T3 (pl) 2020-08-10
WO2016087880A1 (en) 2016-06-09
US20200239453A1 (en) 2020-07-30
US20200399253A1 (en) 2020-12-24
AU2015356795A1 (en) 2017-04-27
US20190023697A1 (en) 2019-01-24
US20200031809A1 (en) 2020-01-30
CN112375073B (zh) 2024-04-16
HUE048905T2 (hu) 2020-08-28
US20190023696A1 (en) 2019-01-24
BR112017008481A2 (pt) 2018-01-09
US11008307B2 (en) 2021-05-18
US10093659B2 (en) 2018-10-09
EA201791174A1 (ru) 2017-10-31
US10487073B2 (en) 2019-11-26
US10450304B2 (en) 2019-10-22
CN112375073A (zh) 2021-02-19
MX370412B (es) 2019-12-11
CN107001343A (zh) 2017-08-01
US20170037035A1 (en) 2017-02-09
SG11201702835RA (en) 2017-05-30
CN107001343B (zh) 2020-12-11
US20210238169A1 (en) 2021-08-05
US20190276441A1 (en) 2019-09-12
DK3227277T3 (da) 2020-04-27
HUE048685T2 (hu) 2020-07-28
MX2017007188A (es) 2017-08-28
KR20170088850A (ko) 2017-08-02
WO2016087878A1 (en) 2016-06-09
US20200002320A1 (en) 2020-01-02
IL251631B (en) 2020-05-31
ES2786374T3 (es) 2020-10-09

Similar Documents

Publication Publication Date Title
KR102579848B1 (ko) 항진균 화합물
US10513511B2 (en) Aqueous suspension formulation comprising 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluoro-phenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl) or a pharmaceutically acceptable salt thereof
NZ730861B2 (en) Antimycotic compound

Legal Events

Date Code Title Description
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant